CN1080853A - N-(膦酰基乙酰基)-l-天冬氨酸组合物及其作为广谱抗病毒的使用方法 - Google Patents

N-(膦酰基乙酰基)-l-天冬氨酸组合物及其作为广谱抗病毒的使用方法 Download PDF

Info

Publication number
CN1080853A
CN1080853A CN93104593A CN93104593A CN1080853A CN 1080853 A CN1080853 A CN 1080853A CN 93104593 A CN93104593 A CN 93104593A CN 93104593 A CN93104593 A CN 93104593A CN 1080853 A CN1080853 A CN 1080853A
Authority
CN
China
Prior art keywords
treatment
days
virus
pala
hcmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93104593A
Other languages
English (en)
Chinese (zh)
Inventor
H·A·布劳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/032,234 external-priority patent/US5491135A/en
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of CN1080853A publication Critical patent/CN1080853A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN93104593A 1992-03-18 1993-03-18 N-(膦酰基乙酰基)-l-天冬氨酸组合物及其作为广谱抗病毒的使用方法 Pending CN1080853A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85345492A 1992-03-18 1992-03-18
US853,454 1992-03-18
US08/032,234 US5491135A (en) 1992-03-18 1993-03-17 Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
US032,234 1993-03-17

Publications (1)

Publication Number Publication Date
CN1080853A true CN1080853A (zh) 1994-01-19

Family

ID=26708159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93104593A Pending CN1080853A (zh) 1992-03-18 1993-03-18 N-(膦酰基乙酰基)-l-天冬氨酸组合物及其作为广谱抗病毒的使用方法

Country Status (10)

Country Link
EP (1) EP0660710A1 (fr)
JP (1) JPH07507770A (fr)
CN (1) CN1080853A (fr)
AU (1) AU3965993A (fr)
BR (1) BR9306123A (fr)
CA (1) CA2109435C (fr)
IL (1) IL105090A (fr)
IS (1) IS3987A (fr)
MX (1) MX9301527A (fr)
WO (1) WO1993018763A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111317733A (zh) * 2020-03-24 2020-06-23 中国人民解放军海军军医大学 利福霉素类抗生素在制备抗黄热病毒感染药物中的应用
CN111419839A (zh) * 2020-03-31 2020-07-17 远见生物科技（上海）有限公司 利福霉素的新用途
WO2021189444A1 (fr) * 2020-03-24 2021-09-30 中国人民解放军海军军医大学 Utilisation d'antibiotiques du type rifamycine dans la préparation de médicaments contre des infections par le virus de la fièvre jaune

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440980B1 (en) * 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
ES2216327T3 (es) 1997-11-10 2004-10-16 G.D. SEARLE & CO. Uso de iminoazucares alquilados para tratar la resistencia a multiples a farmacos.
EP1061922B9 (fr) 1998-02-12 2007-03-07 United Therapeutics Corporation Utilisation de composes n-substitues-1,5-didesoxy-1,5-imino-d-glucitol dans le traitement des infections dues au virus de l'hepatite
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
WO2000047198A2 (fr) 1999-02-12 2000-08-17 G.D. Searle & Co. Utilisation de composes substitues 1,5-dideoxy-1,5-imino-d-glucitol pour traiter les infections par le virus de l'hepatite
EP1173161A2 (fr) 1999-02-12 2002-01-23 G.D. SEARLE & CO. Composes glucamine destines au traitement d'infections dues au virus de l'hepatite
AU2012101A (en) * 1999-12-20 2001-07-03 New Pharma Research Sweden Ab Veterinary compositions
DE10138912A1 (de) * 2001-08-08 2003-02-27 Medinnova Ges Med Innovationen Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
DE10343365A1 (de) * 2003-09-17 2005-04-14 Biosphings Ag Pharmazeutische Formulierungen von Xanthogenaten und Hemmstoffen der viralen Nukleinsäurereplikation
US8236768B2 (en) 2008-10-03 2012-08-07 3B Pharmaceuticals, Inc. Topical antiviral formulations
US20230147364A1 (en) * 2020-04-30 2023-05-11 Kyoto University Prophylactic or therapeutic agent for rna virus-related diseases
WO2022200615A1 (fr) * 2021-03-26 2022-09-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Combinaison d'inhibiteur de la biosynthèse de la pyrimidine destinée à être utilisée dans le traitement d'infections virales

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178306A (en) * 1978-08-10 1979-12-11 Parsons Jack L Preparation of N-(phosphonoacetyl)-L-aspartic acid

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111317733A (zh) * 2020-03-24 2020-06-23 中国人民解放军海军军医大学 利福霉素类抗生素在制备抗黄热病毒感染药物中的应用
WO2021189444A1 (fr) * 2020-03-24 2021-09-30 中国人民解放军海军军医大学 Utilisation d'antibiotiques du type rifamycine dans la préparation de médicaments contre des infections par le virus de la fièvre jaune
CN111317733B (zh) * 2020-03-24 2022-07-12 中国人民解放军海军军医大学 利福霉素类抗生素在制备抗黄热病毒感染药物中的应用
CN111419839A (zh) * 2020-03-31 2020-07-17 远见生物科技（上海）有限公司 利福霉素的新用途

Also Published As

Publication number Publication date
CA2109435C (fr) 1997-03-11
WO1993018763A1 (fr) 1993-09-30
IS3987A (is) 1993-09-19
IL105090A (en) 1998-08-16
AU3965993A (en) 1993-10-21
JPH07507770A (ja) 1995-08-31
EP0660710A4 (fr) 1995-03-02
EP0660710A1 (fr) 1995-07-05
MX9301527A (es) 1994-02-28
BR9306123A (pt) 1997-08-26
IL105090A0 (en) 1994-08-26
CA2109435A1 (fr) 1993-09-19

Similar Documents

Publication Publication Date Title
CN1080853A (zh) N-(膦酰基乙酰基)-l-天冬氨酸组合物及其作为广谱抗病毒的使用方法
CN1668305A (zh) 用于预防hiv性传播的杀微生物嘧啶或三嗪
CN1213746C (zh) 免疫强化剂及其生理上可接受的盐
CN1604906A (zh) 用于治疗单链rna病毒感染的抗病毒反义核酸的试剂和方法
CN1747937A (zh) 预防hiv感染的嘧啶衍生物
CN1258191A (zh) 人免疫缺陷病毒和其它传染性疾病的抗微生物预防和治疗
CN1404480A (zh) 用作pde4同工酶抑制剂的嘧啶甲酰胺
CN1886393A (zh) 含有环烷基或吡喃基基团的atp－结合弹夹转运蛋白的调控剂
CN1419452A (zh) 协同治疗癌症的方法和组合物
CN1208065C (zh) 应用长链烃和核苷类似物协同抑制病毒复制
CN1561204A (zh) Cox－2抑制剂预防免疫缺陷的用途
CN1207683A (zh) 细胞因子和造血因子内源性产生的增强剂及其使用方法
CN1268345C (zh) 治疗丁型肝炎病毒感染的核苷化合物
CN1383452A (zh) 治疗含有双微体dna的细胞的组合物及方法
CN1838947A (zh) 用于治疗或预防严重急性呼吸道综合征(sars)的甘草皂苷或其衍生物
CN1503669A (zh) 抗病毒剂和病毒感染的治疗方法
CN1211089C (zh) 尿苷磷酸化酶抑制剂的制药应用及含其的组合物
CN1726018A (zh) 使用环加氧酶－2选择性抑制剂或环加氧酶－2抑制剂联合抗病毒剂治疗疱疹病毒感染的方法和组合物
CN1711099A (zh) 具有抗肿瘤和抗毒活性的提取物
CN1835942A (zh) 粘蛋白合成抑制剂
CN1313776A (zh) 变态反应性疾病治疗药物
CN1272113A (zh) 作为抗病毒剂的来苏呋喃糖基苯并咪唑类化合物
Zhang et al. Antiviral effect and mechanism of metformin against grouper iridovirus infection
CN1889943A (zh) 协同抗癌组合物
CN1321165A (zh) 病毒性疾病的预防和治疗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication